中国生物制药

Summary of Conference Call Company and Industry - The conference call focuses on China Biopharmaceutical, listed on the Hong Kong Stock Exchange under the ticker 1177 [1] Core Points and Arguments - The analyst indicates that 2023 is a pivotal year for China Biopharmaceutical, marking a period where self-research and business development (BD) strategies are expected to yield significant results [1] - The company is entering a comprehensive harvest phase for its four major innovative products [1] Other Important Content - The emphasis on self-research and BD suggests a strategic shift towards enhancing internal capabilities and expanding through partnerships or acquisitions [1]